Apnimed, Inc.

APMD

Healthcare Biotechnology

Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.

15.10 0.94 +6.64%
Market cap
$628.6M
P/E
0.8×
Fwd P/E
4.3×
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.0×
Dividend safety
n/a
Older periods Jun '25 Dec '25 Mar '26 Jun '26
ROE

+2 more TTM periods

— — — 0.00%
ROA
— — — 0.00%
ROIC
— 0.00% 0.00% 0.00%
Return on Tangible Assets
— 0.00% 0.00% 64.01%
Average Days of Receivables
— 0.00 0.00 2.15
Free Cash Flow per Share
0.00 — 0.00 (17.46)
Free Cash Flow
— — — (83.75)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026